Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Isis licenses anti-HIV drug to ImQuest
ImQuest plans to develop ISIS 5320 as a topical microbicide therapy to prevent the sexual transmission of HIV throughout the world, but especially in developing countries. As part
ImQuest plans to develop ISIS 5320 as a topical microbicide therapy to prevent the sexual transmission of HIV throughout the world, but especially in developing countries. As part
The trial compared Dacogen with supportive care for the treatment of myelodysplastic syndromes (MDS). The drug is currently under review by the FDA for use in this indication.
According to the FDA, Tramadol extended release (ER) was designated a fast track product both because of the seriousness of painful HIV-associated neuropathy and because the treatment demonstrates
The FDA priority review designation establishes a target six-month review period from the date of receipt of the Fibrillex (eprodisate) NDA. Priority review is granted to product candidates
According to the company, the 113,000 square-foot manufacturing facility provides a high degree of accuracy in the manufacturing operation. This supports product safety and operational efficiency as production
Lab-CGRP is a 37 amino acid natural neuropeptide produced in the lung in response to allergic stimuli. As a potential drug, it has demonstrated in preclinical studies a
This is the first data to demonstrate that a bile acid sequestrant (BAS), when added to therapy with a statin such as Merck & Co’s Zocor or Pfizer’s
The participants in the collaboration will evaluate the therapeutic in animal models maintained by the researchers at the US Army Medical Research Institute of Infectious Diseases (USAMRIID). The
CRx-170 is a novel synergistic combination drug candidate containing low dose budesonide and low dose nortriptyline. As measured by forced expiratory volume (FEV1), the standard clinical measure of
Guangxi Lingfeng Pharmaceutical (GLP), founded in 1975 and organized under the laws of China, specializes in manufacturing and distribution of plant-based medicines in China. Over the past 30